Savient regains compliance with Nasdaq listing requirements

By Jennifer Chiou

New York, Jan. 31 - Savient Pharmaceuticals, Inc. announced it received written notice from the Nasdaq listing qualifications panel that it is in compliance with requirements for continued listing on The Nasdaq National Market.

On Jan. 26, the company had said it believed it was in compliance with listing requirements with the filing of its 10-Q for the third quarter of 2005 with the Securities and Exchange Commission.

At the time, the 10-Q filing, as well as Savient's 2005 10-K amendment and its 10-Q for the quarters ended March 31 and June 30, 2005, remained subject to review by the Nasdaq staff to determine completion.

The company will resume trading under "SVNT."

Savient Pharmaceuticals is an emerging specialty pharmaceuticals company based in East Brunswick, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.